Arcturus Therapeutics Holdings Inc. (ARCT) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 11.85
30Y Low11.8·High11.8
P/FCF
N/A
—
5yr avg: 18.94
30Y Low18.9·High18.9
P/B Ratio
↓
0.96
↓-59% vs avg
5yr avg: 2.33
30Y Low0.7·High5.1
ROE
↑
-28.9%
-9% vs avg
5yr avg: -26.5%
30Y Low-399%·High4%
Debt/EBITDA
N/A
—
5yr avg: 6.91
30Y Low6.9·High6.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ARCT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Arcturus Therapeutics Holdings Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $214M | $168M | $458M | $840M | $459M | $974M | $881M | $131M | $46M | $25M | $58M |
| Enterprise Value | $8M | $-38034820 | $250M | $578M | $162M | $673M | $439M | $81M | $19M | $-423350 | $56M |
| P/E Ratio → | -3.14 | — | — | — | 48.46 | — | — | — | — | — | — |
| P/S Ratio | 3.18 | 2.50 | 3.31 | 5.32 | 2.23 | 78.81 | 92.34 | 6.31 | 2.90 | 1.89 | 2.84 |
| P/B Ratio | 0.96 | 0.78 | 1.90 | 3.01 | 1.70 | 4.27 | 2.22 | 5.09 | 3.34 | 0.73 | 1.23 |
| P/FCF | — | — | — | — | 18.94 | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 14.36 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ARCT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.57 | 1.80 | 3.66 | 0.79 | 54.43 | 45.99 | 3.87 | 1.19 | -0.03 | 2.73 |
| EV / EBITDA | — | — | — | — | 11.85 | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 13.33 | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | 6.69 | — | — | — | — | — | — |
ARCT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Arcturus Therapeutics Holdings Inc. earns an operating margin of -111.5%. Operating margins have compressed from -49.6% to -111.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -28.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.5% | 95.5% | 100.0% | 100.0% | 100.0% | 100.0% | -486.5% | 100.0% | -7.8% | 96.8% | 98.6% |
| Operating Margin | -111.5% | -111.5% | -69.1% | -49.6% | 5.9% | -1641.3% | -749.8% | -122.7% | -138.5% | -80.7% | -123.5% |
| Net Profit Margin | -97.9% | -97.9% | -58.5% | -18.8% | 4.5% | -1648.0% | -756.3% | -125.0% | -138.3% | -83.9% | -120.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -28.9% | -28.9% | -31.2% | -10.8% | 3.8% | -65.2% | -34.2% | -131.8% | -91.9% | -26.9% | -42.2% |
| ROA | -21.4% | -21.4% | -20.9% | -6.8% | 2.2% | -46.9% | -25.8% | -41.1% | -45.3% | -21.0% | -39.9% |
| ROIC | -277.1% | -277.1% | -291.5% | -350.7% | — | — | — | — | — | -29.2% | -38.6% |
| ROCE | -29.2% | -29.2% | -30.6% | -23.3% | 3.9% | -56.3% | -29.3% | -55.2% | -60.1% | -23.8% | -43.2% |
ARCT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $231M exceeds total debt of $25M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.12 | 0.11 | 0.35 | 0.30 | 0.05 | 0.80 | 0.73 | — | 0.00 |
| Debt / EBITDA | — | — | — | — | 6.91 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.96 | -0.87 | -0.94 | -1.10 | -1.32 | -1.11 | -1.96 | -1.96 | -0.74 | -0.05 |
| Net Debt / EBITDA | — | — | — | — | -21.68 | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -12.24 | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -35.36 | 4.06 | -75.86 | -86.07 | -29.43 | -114.50 | -71.67 | -4.21 |
Net cash position: cash ($231M) exceeds total debt ($25M)
ARCT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Arcturus Therapeutics Holdings Inc.'s current ratio of 6.64x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.72x to 6.64x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.64 | 6.64 | 4.67 | 4.72 | 3.18 | 3.81 | 9.45 | 3.48 | 3.33 | 4.61 | 11.82 |
| Quick Ratio | 6.64 | 6.64 | 4.67 | 4.72 | 3.18 | 3.81 | 9.45 | 3.48 | 3.33 | 4.48 | 11.94 |
| Cash Ratio | 6.35 | 6.35 | 3.62 | 3.56 | 3.09 | 3.72 | 9.35 | 3.35 | 2.92 | 4.40 | 11.58 |
| Asset Turnover | — | 0.25 | 0.40 | 0.37 | 0.46 | 0.03 | 0.02 | 0.25 | 0.36 | 0.25 | 0.40 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 0.28 | — |
| Days Sales Outstanding | — | 30.21 | 10.48 | 74.19 | 4.90 | 99.44 | 81.31 | 38.26 | 103.83 | 13.48 | 65.06 |
ARCT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Arcturus Therapeutics Holdings Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 2.1% | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | 5.3% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $27M | $27M | $27M | $27M | $26M | $20M | $12M | $10M | $3M | $4M |
Peer Comparison
Compare ARCT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ARCTYou | $214M | -3.1 | — | — | 95.5% | -111.5% | -28.9% | -277.1% | — |
 MRNA | $25B | -8.8 | — | — | 55.3% | -158.1% | -28.9% | -26.1% | — |
 BNTX | $23B | -17.6 | — | 74.4 | 77.6% | -22.6% | -5.7% | -4.3% | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 ALNY | $37B | 119.4 | 65.9 | 79.7 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 IONS | $12B | -31.1 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ARWR | $12B | -6706.6 | 95.4 | 73.5 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 REGN | $63B | 14.7 | 15.3 | 15.5 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 EDIT | $263M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ARCT — Frequently Asked Questions
Quick answers to the most common questions about buying ARCT stock.
What is Arcturus Therapeutics Holdings Inc.'s P/E ratio?
Arcturus Therapeutics Holdings Inc.'s current P/E ratio is -3.1x. The historical average is 48.5x.
What is Arcturus Therapeutics Holdings Inc.'s ROE?
Arcturus Therapeutics Holdings Inc.'s return on equity (ROE) is -28.9%. The historical average is -74.4%.
Is ARCT stock overvalued?
Based on historical data, Arcturus Therapeutics Holdings Inc. is trading at a P/E of -3.1x. Compare with industry peers and growth rates for a complete picture.
What are Arcturus Therapeutics Holdings Inc.'s profit margins?
Arcturus Therapeutics Holdings Inc. has 95.5% gross margin and -111.5% operating margin.